FindMyKOL
Clinical trialNCT06014502RecruitingPhase 1Interventional

Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

NCT06014502 is a phase 1 interventional trial sponsored by ImmunoGenesis. As of 21 Nov 2026, it is recruiting participants. It studies IMGS-001 in Solid Tumor. The registry lists an enrollment of 105 participants at 13 sites in 1 country. The registry lists a start date of 7 Sept 2023 and a primary completion date of 31 Dec 2027. One of its registered investigators has a FindMyKOL profile.

SponsorImmunoGenesis →Enrollment105Solid Tumor
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06014502
FieldValue
Registry IDNCT06014502
StatusRecruiting
PhasePhase 1
Study typeInterventional trial
Lead sponsorImmunoGenesis
Enrollment105
Registered sites13
Countries1
ConditionsSolid Tumor
DrugsIMGS-001
Start7 Sept 2023
Primary completion31 Dec 2027
Study completion31 Dec 2028
Last update posted4 Sept 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational drug called IMGS-001 and to determine how well it can work in treating patients with advanced solid tumors that have come back or are not improving after receiving other drugs that are commonly used for their cancer. Phase 1a (Part 1) will test the safety of five different doses of IMGS-001 to use in further studies. Patients with cancer that have advanced or spread to other parts of the body following treatment with other available therapies will be treated in Part 1. Phase 1b (Part 2) will test two doses of IMGS-001 identified in Part 1 to further determine the safety and potential effectiveness in select cancer types.

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Arizona, United States1 site, 1 recruiting
  • Banner Md Anderson Cancer Center

    Gilbert

    Madappa Kundranda, MD
    Recruiting
California, United States2 sites, 2 recruiting
  • Uc Irvine

    Orange

    Victoria Villaflor, MD
    Recruiting
  • Sarcoma Oncology Center

    Santa Monica

    Neal S. Chawla, MD
    Recruiting
Florida, United States1 site, 1 recruiting
  • Moffitt Cancer Center

    Tampa

    Robin Park, MD
    Recruiting
Kentucky, United States1 site, 1 recruiting
  • St. Elizabeth Healthcare

    Edgewood

    Daniel Flora, MD
    Recruiting
Louisiana, United States1 site, 1 recruiting
  • Ochsner Clinic Foundation

    New Orleans

    Daniel Johnson, MD
    Recruiting
Missouri, United States1 site, 1 recruiting
  • Washu

    St Louis

    Brendan J Knapp, MD
    Recruiting
Pennsylvania, United States2 sites, 2 recruiting
  • Fox Chase Cancer Center

    Philadelphia

    Parth A Desai, MBBS, MD
    Recruiting
  • Upmc Hillman Cancer Center

    Pittsburgh

    Diwakar Davar, MBBS, MSc
    Recruiting
Texas, United States3 sites, 3 recruiting
  • Md Anderson Cancer Center

    Houston

    David S. Hong, MD
    Recruiting
  • Next Dallas

    Irving

    Shiraj Sen, MD
    Recruiting
  • Texas Oncology

    Tyler

    Donald Richards, MD, PhD
    Recruiting
Virginia, United States1 site, 1 recruiting
  • Virginia Oncology Associates

    Norfolk

    Jedrzej Wykretowicz, MD, PhD
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvania: 2 sites, 2 recruitingPA2New JerseyNJConnecticutCTCalifornia: 2 sites, 2 recruitingCA2NevadaNVWyomingWYNebraskaNEMissouri: 1 site, 1 recruitingMO1Kentucky: 1 site, 1 recruitingKY1West VirginiaWVVirginia: 1 site, 1 recruitingVA1MarylandMDDelawareDEArizona: 1 site, 1 recruitingAZ1UtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisiana: 1 site, 1 recruitingLA1MississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 3 sites, 3 recruitingTX3Florida: 1 site, 1 recruitingFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

IMGS-001
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06014502

Each answer restates registry values shown on this page.

What is NCT06014502?

NCT06014502 is a phase 1 interventional trial sponsored by ImmunoGenesis. It studies IMGS-001 in Solid Tumor.

Is NCT06014502 recruiting?

As of 21 Nov 2026, it is recruiting participants. 13 of its 13 sites list their own status as recruiting.

Where does NCT06014502 run?

The registry lists 13 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT06014502 study?

The registered drug and biological interventions are IMGS-001.

When is NCT06014502 expected to complete?

The registry lists a primary completion date of 31 Dec 2027 and a study completion date of 31 Dec 2028. The sponsor last updated the record on 4 Sept 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.